Service Platform
Related Services and Solutions
We look forward to working with you and providing you with excellent service.
Product Series
| Indication | Product | Dosage Form | Strength & Package form | Intended Market | Status |
| Anti-epilepsy | Carbamazepine | Sustained Release Tablets | 100mg, 200mg & 400mg 100CT/Bottle | US/China | FDA: Approved NMPA: Approved |
| Oxcarbazepine | Tablets | 150mg, 300mg Blister | China | 150 mg: Under review 300 mg: Approved | |
| Oxcarbazepine | Oral suspension | 100 ml: 6 g | China | Under Review | |
| Lacosamide | Tablets | 50mg, 100mg Blister | China | Approved | |
| Antidiabetic | Sitagliptin + Metformin | Sustained Release Tablets | US market: 100/1000, 50/1000 China: 100/1000, 50/1000, 50/500 | US/China | FDA: Under review NMPA: Under review |
Sitagliptin Phosphate | Tablets | 50mg, 100mg Blister | China | Approved | |
Sitagliptin + Metformin | Tablets | 50mg/850mg Blister | China | Approved | |
| Gliclazide | Sustained Release Tablets | 60mg Blister | China | Approved | |
Dapagliflozin + Metformin | Sustained Release Tablets | 5mg/500mg 5mg/1000mg 10mg/500mg 10mg/1000mg Blister | China | To be submitted in Nov. 2025 | |
| Antidepressant | Venlafaxine Hydrochloride | Sustained Release Capsules | 75mg Blister | China | Approved |
Vortioxetine Hydrobromide | Tablets | 5mg, 10mg Blister | China | Under Review | |
| Anticoagulant | Edoxaban Tosylate | Tablets | 30mg, 60mg Blister | China | Under Review |
| ED | Sildenafil Citrate | Orally Disintegrating Tablets | 50mg Blister | China | Approved |
| PD | Rasagiline Mesylate | Tablets | 1mg Blister | China | Under Review |
| Potassium-competitive acid blocker | Vonoprazan Fumarate | Tablets | 10mg, 20mg Blister | China | Under Review |
| Anti-anxiety | Tandospirone Citrate | Tablets | 5mg, 10mg Blister | China | Under Review |
| Anti-influenza | Baloxavir Marboxil | Tablets | 20mg, 40mg Blister | China | Under Review |
| NSAIDs | Diclofenac Diethylamine | Gel Topical | 1%: 20g/tube, 50g/tube 2.32%: 50g/tube | China | 1%: To be submitted in Mar. 2026; 2.32%: To be submitted in Nov. 2025 |
| NSAIDs | Ketoprofen | Gel Topical | 2.5%: 20g/tube, 50g/tube | China | To be submitted in Nov. 2025 |
Business Collaboration
Innovative Drug CDMO Services
Tel: 86-576-85588039
E-mail: bd@jiuzhoupharma.com
